title: A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
abstract: OBJECTIVE
  Alosetron is indicated for women with chronic, severe diarrhea-predominant IBS (d-IBS) who have not responded adequately to conventional therapy. Constipation is the most common adverse event with alosetron treatment. Multiple dosing regimens were assessed in a randomized, double-blind, placebo-controlled study (S3B30040) to determine efficacy, tolerability, and evaluate constipation rate.
  
  
  METHODS
  705 women with severe d-IBS were randomized to placebo, alosetron 0.5 mg once daily, 1 mg once daily, or 1 mg twice daily for 12 wk. The primary end point was the proportion of week 12 responders (patients with moderate or substantial improvement in IBS symptoms) on the 7-point Likert Global Improvement Scale (GIS). Secondary end points were average rate of adequate relief of IBS pain and discomfort, and bowel symptom improvements.
  
  
  RESULTS
  The proportion of GIS responders at week 12 (primary time point) was significantly greater in all alosetron groups compared with placebo (54/176 [30.7%], 90/177 [50.8%], 84/175 [48%], and 76/177 [42.9%] for placebo, 0.5, 1 mg once daily, and 1 mg twice daily alosetron groups, respectively; P< or = 0.02). Results were similar for the average adequate relief rate (treatment effects > or =12%, P< or = 0.038). Bowel symptoms were improved in all alosetron groups. Constipation was the most common adverse event (9%, 16%, and 19% patients in the 0.5 mg, 1 mg once daily, and 1 mg twice daily groups, respectively). One event of intestinal obstruction and one of ischemic colitis occurred in the 0.5 mg group, and one event of fecal impaction occurred in the 1 mg twice-daily group. All were self-limited and resolved without sequelae.
  
  
  CONCLUSIONS
  Alosetron 0.5 mg and 1 mg once daily as well as 1 mg twice daily are effective in providing global improvement in IBS symptoms, adequate relief of IBS pain and discomfort, and improvement in bowel symptoms in women with severe d-IBS. Lower dosing regimens resulted in a decreased constipation rate.
authors.affiliation: ClinSearch, Chattanooga, Tennessee, USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Krause
authors.forename: Vanessa
authors.initials: V
authors.lastname: Ameen
authors.forename: Susan H
authors.initials: SH
authors.lastname: Gordon
authors.forename: Marquita
authors.initials: M
authors.lastname: West
authors.forename: Amy T
authors.initials: AT
authors.lastname: Heath
authors.forename: Teresa
authors.initials: T
authors.lastname: Perschy
authors.forename: Eric G
authors.initials: EG
authors.lastname: Carter
mesh_terms: D002243:Carbolines / Q000008:administration & dosage* / Q000009:adverse effects; D003248:Constipation / Q000139:chemically induced; D003967:Diarrhea / Q000188:drug therapy; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D008875:Middle Aged; D012702:Serotonin Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D002243:Carbolines; D005765:Gastrointestinal Agents; D012702:Serotonin Antagonists; C090840:alosetron